Intravenous ascorbic acid: protocol for its application and use.

Hugh D Riordan; Ronald B Hunninghake; Neil H Riordan; James J Jackson; Xiaolong Meng; Paul Taylor; Joseph J Casciari; Michael J González; Jorge R Miranda-Massari; Edna M Mora; Norberto Rosario; Alfredo Rivera

PubMed · 14619456

Intravenous ascorbic acid: protocol for its application and use.

Hugh D Riordan·Ronald B Hunninghake·Neil H Riordan·James J Jackson·Xiaolong Meng·Paul Taylor·Joseph J Casciari·Michael J González·Jorge R Miranda-Massari·Edna M Mora·Norberto Rosario·Alfredo Rivera

View original source ↗Export metadata ↓

Abstract

High dose intravenous(i.v.) ascorbic acid (AA) has been used as therapy for infectious disease from bacterial and viral origin and adjuvant therapy for cancer. In this publication we describe a clinical protocol that has been developed over the past twenty years utilizing high dose i.v. AA as therapy for cancer. This includes principles of treatment, rationale, baseline workup, infusion protocol, precautions and side effects.

Explore related subjects

Anti-Infective Agents Antineoplastic Agents Ascorbic Acid Bacterial Infections Clinical Protocols Dose-Response Relationship, Drug Humans Infusions, Intravenous Neoplasms Neoplastic Stem Cells Virus Diseases Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Hugh D Riordan, Ronald B Hunninghake, Neil H Riordan, James J Jackson, Xiaolong Meng, Paul Taylor, Joseph J Casciari, Michael J González, Jorge R Miranda-Massari, Edna M Mora, Norberto Rosario, Alfredo Rivera. 2003. Intravenous ascorbic acid: protocol for its application and use.. https://pubmed.ncbi.nlm.nih.gov/14619456/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels.

BACKGROUND: Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. Methemoglobinemia is a known complication of dapsone, but its true frequency and pathogenesis in childhood cancer patients are unknown. Additionally, practice guidelines for evaluation and management of dapsone-induced methemoglobinemia are not available. PROCEDURE: We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels. Ten children with ALL receiving trimethoprim-sulfamethaxazole (TMP-SMX) were studied as controls. All patients underwent physical examination, pulse oximetry, and methemoglobin (metHb) estimation. Commercially available assay was used to measure Cb5R levels. RESULTS: Three (20%) patients receiving dapsone developed symptomatic methemoglobinemia. Average duration of dapsone prophylaxis prior to diagnosis was 6.6 weeks (range 3.5-10 weeks). Mean metHb level in symptomatic patients was 11.67%; 95% confidence interval (CI) 0-25.79 (range 7-18%), and 1.37%; 95% CI 0.6-2.14 (range 0.02-3%) in asymptomatic patients (P = 0.09), whereas the mean metHb level in the control group was 0.54%; 95% CI 0.35-0.73 (range 0.1-0.8%) (asymptomatic vs control P < 0.0001). Mean Cb5R level in symptomatic patients was 8.6 IU/g Hb; 95% CI 3.4-13.7 (range 6.9-10.9) compared to 12.5 IU/g Hb; 95% CI 11.1-13.9 (range 10.8-14.6) in asymptomatic patients (P = 0.06). Two symptomatic patients had Cb5R levels at or below 50% of normal, consistent with heterozygosity. Parental studies for Cb5R levels were suggestive of a carrier state in one of each patient's parents. CONCLUSIONS: Heterozygosity for Cb5R deficiency may pre-dispose to methemoglobinemia even on a thrice-weekly regimen of dapsone. Such individuals should avoid subsequent exposure to oxidant agents, if possible. Children with ALL tend to be symptomatic at low levels of metHb and may have delayed detection of methemoglobinemia. Hence, frequent monitoring of patients receiving dapsone is recommended. Monitoring guidelines for dapsone prophylaxis are proposed.

Anti-Infective Agents↗

PubMed2004

Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.

A series of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position were synthesized to obtain potent drugs for the treatment of Gram-positive infections. Some compounds exhibited excellent antibacterial activity, and potent inhibitory activity against bacterial DNA topoisomerase IV. In addition, some of the potent compounds showed reduced inhibitory activity against human DNA topoisomerase II compared with the corresponding noncyclopropane-fused compounds.

Anti-Infective Agents↗

PubMed2004

Role of hydrochloric acid in the treatment of central venous catheter infections in children with cancer.

BACKGROUND: The use of central venous catheters (CVCs) in pediatric cancer patients is associated with substantial risk of producing sepsis. The treatment of catheter-related infections has generally consisted of antibiotic administration with or without catheter removal. The authors report the first published experience using intraluminal hydrochloric acid (HCl) instillation as an adjunct to systemic antimicrobials in the management of catheter-related infections in children with cancer. METHODS: All episodes of intraluminal instillation of 2 M HCl in oncology patients at The Children's Hospital at Westmead between December 1994 and August 2000 were reviewed. Episodes of HCl use were identified from a prospectively maintained infection data base. Successful treatment was defined as no recurrence of infection and no need for CVC removal in the 100 days after HCl administration. RESULTS: Forty-two episodes of HCl instillation were evaluated that occurred in children in whom blood cultures remained positive despite 48 hours of appropriate, systemic antibiotics and formed the basis of this review. All patients had in situ a surgically placed, subcutaneously tunneled CVC. The combination of systemic antibiotic therapy and HCl instillation was successful in eradicating infection in 67% of infection episodes in this patient cohort. The catheter salvage rate was 83% in patients with isolated Gram-negative infections, 75% in patients with isolated fungemia, and 50% in patients with isolated Gram-positive infections. CONCLUSIONS: The results suggest that HCl instillation is a useful adjunct to systemic antibiotic therapy, enabling both catheter salvage and eradication of antibiotic-refractory catheter-related infection.

Anti-Infective Agents↗